Estrella Immunopharma Files 8-K
Ticker: ESLAW · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1844417
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: ESLA
TL;DR
Estrella Immunopharma (ESLA) filed an 8-K on 4/10/24 with Reg FD disclosures and financials.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on April 10, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as TradeUP Acquisition Corp. until February 4, 2021, is based in Emeryville, CA, and operates in the Biological Products sector.
Why It Matters
This filing provides important updates on regulatory disclosures and financial statements for Estrella Immunopharma, Inc., which is crucial for investors to understand the company's current status and compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, primarily containing disclosures and exhibits, without immediate significant financial or operational news.
Key Numbers
- 001-40608 — SEC File Number (Identifies the company's filing with the SEC)
- 86-1314502 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- TradeUP Acquisition Corp. (company) — Former company name
- April 10, 2024 (date) — Date of earliest event reported
- 5858 Horton Street, Suite 370 (address) — Company business and mail address
- Emeryville, CA (location) — Company city and state
FAQ
What specific Regulation FD disclosures are being made in this 8-K filing?
The filing indicates a 'Regulation FD Disclosure' as an item, but the specific details of the disclosure are not provided in the header information.
What are the key financial statements or exhibits included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided header.
When did Estrella Immunopharma, Inc. change its name from TradeUP Acquisition Corp.?
The company changed its name from TradeUP Acquisition Corp. on February 4, 2021.
What is Estrella Immunopharma, Inc.'s fiscal year end?
Estrella Immunopharma, Inc.'s fiscal year ends on June 30.
What is the SIC code for Estrella Immunopharma, Inc.?
The Standard Industrial Classification (SIC) code for Estrella Immunopharma, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-04-10 06:14:14
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
Filing Documents
- ea0203610-8k_estrella.htm (8-K) — 30KB
- ea020361001ex99-1_estrel.htm (EX-99.1) — 46KB
- ex99-1_001.jpg (GRAPHIC) — 248KB
- ex99-1_002.jpg (GRAPHIC) — 403KB
- ex99-1_003.jpg (GRAPHIC) — 331KB
- ex99-1_004.jpg (GRAPHIC) — 211KB
- ex99-1_005.jpg (GRAPHIC) — 339KB
- ex99-1_006.jpg (GRAPHIC) — 289KB
- ex99-1_007.jpg (GRAPHIC) — 264KB
- ex99-1_008.jpg (GRAPHIC) — 152KB
- ex99-1_009.jpg (GRAPHIC) — 289KB
- ex99-1_010.jpg (GRAPHIC) — 309KB
- ex99-1_011.jpg (GRAPHIC) — 275KB
- ex99-1_012.jpg (GRAPHIC) — 340KB
- ex99-1_013.jpg (GRAPHIC) — 282KB
- ex99-1_014.jpg (GRAPHIC) — 312KB
- ex99-1_015.jpg (GRAPHIC) — 137KB
- ex99-1_016.jpg (GRAPHIC) — 276KB
- ex99-1_017.jpg (GRAPHIC) — 284KB
- ex99-1_018.jpg (GRAPHIC) — 150KB
- ex99-1_019.jpg (GRAPHIC) — 313KB
- ex99-1_020.jpg (GRAPHIC) — 148KB
- ex99-1_021.jpg (GRAPHIC) — 268KB
- ex99-1_022.jpg (GRAPHIC) — 244KB
- ex99-1_023.jpg (GRAPHIC) — 191KB
- ex99-1_024.jpg (GRAPHIC) — 354KB
- ex99-1_025.jpg (GRAPHIC) — 325KB
- ex99-1_026.jpg (GRAPHIC) — 411KB
- ex99-1_027.jpg (GRAPHIC) — 135KB
- ex99-1_028.jpg (GRAPHIC) — 260KB
- ex99-1_029.jpg (GRAPHIC) — 236KB
- 0001213900-24-031716.txt ( ) — 11016KB
- esla-20240410.xsd (EX-101.SCH) — 4KB
- esla-20240410_def.xml (EX-101.DEF) — 26KB
- esla-20240410_lab.xml (EX-101.LAB) — 36KB
- esla-20240410_pre.xml (EX-101.PRE) — 25KB
- ea0203610-8k_estrella_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 10, 2024, Estrella Immunopharma, Inc. (the " Company ") posted to the Company's website at www.estrellabio.com an investor presentation to be used from time to time in meetings with investors and analysts. A copy of the investor presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in Exhibit 99.1 is being furnished under Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation dated April 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Cheng Liu Name: Dr. Cheng Liu Title: Chief Executive Officer Date: April 10, 2024 2